Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Microarrays & Multiplexing » Finland's Negen Introduces Pharmacogenomics Panel for COVID-19 Therapies

Finland's Negen Introduces Pharmacogenomics Panel for COVID-19 Therapies

Apr 23, 2020
|
Justin Petrone

NEW YORK – Finnish genetic testing firm Negen has rolled out a pharmacogenomics panel designed to help guide decisions in treating patients with SARS-CoV-2. The Helsinki-based firm is making its panel available for free to people who already have been genotyped by consumer genomics services or biobanks.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Mix of Human and Monkey

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

Fetal Tissue Policy Changes Expected

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

Science Papers on Approach to Isolate DNA from Sediment, Algorithm to Construct Signaling Networks

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Sequencing the Zoo

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.

May
05
Featured Webinar

Establishing a Pharmacogenomic Service for Routine Clinical Care

Sponsored by
Illumina

Adverse drug reactions (ADRs) are responsible for around 5 percent of hospital admissions and occur in 6 percent to 15 percent of hospital stays.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.